Cerecor is a biopharmaceutical company. The company is building a pipeline of therapies in neurology, pediatric healthcare, and orphan rare diseases. The company's neurology pipeline is led by CERC-301, which is in a Phase I safety study for Neurogenic Orthostatic Hypotension. The company is also developing two other neurological clinical and preclinical stage compounds. The company's pediatric orphan rare disease pipeline is led by CERC-801, CERC-802 and CERC-803. All three of these compounds are preclinical therapies for inherited metabolic disorders known as Congenital Disorders of Glycosylation by means of substrate replacement therapy.

DISH Network is a holding company. Through its subsidiaries, the company operates two business segments: Pay-TV and Wireless. The company provides pay-TV services under: the DISH? brand, which consists of, among other things, Federal Communications Commission licenses authorizing the company to use direct broadcast satellite and Fixed Satellite Service spectrum, the company's owned and leased satellites, and certain other assets utilized in the company's operations; and the Sling? brand, which consists of, among other things, live-linear streaming over-the-top Internet-based domestic, international and Latino video programming services. In addition, the company invests to acquire certain wireless spectrum licenses and related assets.

Edgewater Technology helps the C-suite drive transformational change through its selection of business and technology services and channel-based solutions. The company has three segments: Enterprise Performance Management, which provides Business Analytics solutions leveraging Oracle EPM, BI and Big Data technologies; Enterprise Resource Planning, which delivers Dynamics AX ERP, Business Intelligence and CRM solutions in the manufacturing space; and Classic Consulting, which provides business advisory services to help organizations leverage investments in IT assets to create new digital business models. The company's service categories are: Classic consulting services and Product-based consulting services.

Fate Therapeutics is a biopharmaceutical company. The company's off-the-shelf, induced pluripotent stem cells (iPSC)-derived cellular immunotherapy pipeline include: FT500, which is an off-the-shelf natural killer (NK) cell cancer immunotherapy for the treatment of solid tumors; and FT516, which is an off-the-shelf NK cell cancer immunotherapy. The company's other iPSC-derived cell product candidates include: FT301, an off-the-shelf, immuno-regulatory cell product candidate derived from a clonal master iPSC line. The company's allogeneic cellular immunotherapy pipeline include: ProTmune?, an investigational programmed cellular immunotherapy for use as an allogeneic hematopoietic cell transplantation cell graft.

Fluidigm creates, manufactures, and markets a range of products and services, including instruments, reagents and software that are used by researchers worldwide. The company markets technologies and life science tools, including preparatory and analytical instruments for Mass Cytometry, polymerase chain reaction, Library Prep, Single Cell Genomics, and consumables, including integrated fluidic circuits, assays, and reagents. The company's product offerings include: Mass Cytometry, Microfluidics and Single Cell Microfluidics.

Kingsway Financial Services is a holding company. Through its subsidiaries, Co. operates as a merchant bank engaged in the property and casualty insurance business. Co. operates three segments: Insurance Underwriting, which markets automobile insurance products that provide coverage in three main areas: liability, accident benefits and physical damage; Insurance Services, which includes IWS Acquisition Corporation, a licensed motor vehicle service agreement company, and Trinity Warranty Solutions LLC, a provider of warranty products and maintenance support; and Leased Real Estate, which includes Co.'s subsidiary, CMC Industries, Inc., that owns a parcel of real property located in Texas.

Net 1 UEPS Technologies provides financial technology, products and services. The company has developed and owns most of its payment technologies, and where possible, utilizes this technology to provide financial and services to its customers by including them into the formal financial system. The company's primary payment technology is called the Universal Electronic Payment System (UEPS), and its EMV interoperable derivative, UEPS/EMV, utilizes a form of distributed ledger technology, providing decentralized and biometrically secure smart cards that operate in real-time but both off-line and on-line. The company's financial inclusion products and services are delivered through its UEPS-based core banking system.

Synaptics is a developer and supplier of custom-designed human interface semiconductor product solutions that enable people to interact with a variety of mobile computing, communications, entertainment, and other electronic devices. The company targets the markets for smartphones, tablets, personal computer, products, Internet of Things, products and other select electronic devices, including devices in automobiles. The company's family of products includes: ClearPad?, ClearView?, TouchView?, Natural ID?, TouchPad?, SecurePad?, ClickPad?, ForcePad?, AudioSmart?, VideoSmart?, ImagingSmart?, and other product solutions.